Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.
- FY26 revenue increased to A$4.05 million from A$1.39 million
- Network expanded to 18 beds and 138 patients treated
- Sydney clinic fitted out with four treatment rooms
- First workers compensation patients approved for treatment
- FY27 focus shifts to utilisation, reimbursement and further expansion
Revenue growth meets Sydney launch
Emyria Limited (ASX:EMD) is entering FY27 with a larger clinic footprint and a new Sydney beachhead after reporting FY26 revenue of A$4.05 million, up from A$1.39 million a year earlier. The company says it treated 138 patients during the year, compared with one patient reported for FY25, while expanding bed capacity from four to 18.
The next operational milestone is close at hand. Emyria’s first New South Wales clinic has completed its fit-out, with four treatment rooms furnished and equipped ahead of a planned September opening. Around 20 Sydney-based therapists and four psychiatrists have been recruited and trained, while two Sydney psychiatrists have received Therapeutic Goods Administration endorsement as Authorised Prescribers.
Patients approved through the workers compensation pathway are expected to begin treatment shortly after the clinic opens. Emyria has also secured medication and pharmacy arrangements and signed a formal agreement with Matilda Nepean Private Hospital, giving the launch a more developed operating base than a simple property opening.
Capacity has expanded faster than utilisation
Emyria’s FY26 presentation points to a substantial build-out in clinical infrastructure. The company reports five operational or announced clinics, approximately 145 trained clinicians, 17 Authorised Prescribers and 18 beds, although some of these figures include sites or personnel announced after 30 June 2026 rather than capacity fully contributing to the reported year.
Its treatment model involves screening and preparation, supervised dosing and follow-up over an extended patient journey. Emyria estimates revenue of about A$10,000 per dosing day, with total treatment costs of approximately A$33,000 for PTSD and A$22,000 for treatment-resistant depression. Those figures describe the company’s stated treatment economics, not reported profit margins.
The presentation places projected standalone clinic break-even around nine to 12 months after set-up, following a staged ramp from fit-out and recruitment to screening, dosing and higher utilisation. No profit, cash balance or funding requirement was provided in the material, leaving the relationship between revenue growth, clinic utilisation and cash consumption unresolved.
Payer access and therapy programs shape FY27
Emyria says FY26 also brought a Medibank agreement, access to government funding through the Department of Veterans’ Affairs and clinically significant results from its PTSD and treatment-resistant depression programs. The presentation does not provide detailed financial terms for those reimbursement arrangements or the underlying clinical datasets, so their eventual contribution to patient volumes and revenue remains to be demonstrated.
For FY27, the company intends to increase utilisation at existing Australian clinics, continue expanding its network, pursue additional reimbursement pathways and advance its drug-development programs through targeted non-dilutive funding. It is also exploring opportunities in New Zealand and the United States and plans to grow its Empax Global Partnership Program.
The opportunity is paired with material clinical and regulatory caveats. Emyria states that products containing MDMA, psilocybin or MDMA-inspired compounds have not been evaluated by the TGA for quality, safety and efficacy, and that the risk profile of its MDMA-inspired compounds is unknown. The company’s current progress is therefore primarily an operating and access story; the harder question is whether that infrastructure can translate into repeatable, funded treatment volumes.
Bottom Line?
Sydney should provide the clearest near-term test of Emyria’s model: whether a completed clinic, trained workforce and payer pathways can convert into sustained dosing utilisation and progress towards the company’s projected break-even timeframe.
Questions in the middle?
- How quickly will the Sydney clinic move from approved patients to consistent dosing-day utilisation?
- What revenue contribution and payment terms will come from Medibank, workers compensation and DVA pathways?
- Can Emyria fund further clinic and drug-development expansion without a capital raise or slower rollout?